COMMUNIQUÉS West-GlobeNewswire

-
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
06/02/2024 -
GRANT OF PERFORMANCE SHARE UNITS
06/02/2024 -
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
06/02/2024 -
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/02/2024 -
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
06/02/2024 -
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
06/02/2024 -
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06/02/2024 -
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
06/02/2024 -
BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
06/02/2024 -
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
06/02/2024 -
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
06/02/2024 -
Evaxion Announces Closing of $15 Million Public Offering
06/02/2024 -
NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
06/02/2024 -
Gallant Therapeutics Adds Animal Health Executive Aaron Schacht to Board of Directors
06/02/2024 -
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
06/02/2024 -
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
06/02/2024 -
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
06/02/2024 -
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
06/02/2024 -
Cancer and Blood Specialists of Georgia Opens New Oncology Clinic in Cumming
06/02/2024
Pages